MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

A

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Search

Travere Therapeutics Inc

Open

24.9 2.55

Overview

Share price change

24h

Current

Min

23.91

Max

24.79

Key metrics

By Trading Economics

Income

28M

-13M

Sales

33M

114M

Profit margin

-11.145

Employees

385

EBITDA

13M

-13M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+40.26% upside

Dividends

By Dow Jones

Next Earnings

30 paź 2025

Market Stats

By TradingEconomics

Market Cap

838M

2.3B

Previous open

22.35

Previous close

24.9

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Travere Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 lut 2025, 13:58 UTC

Major Market Movers

Travere to Seek FDA OK of Filspari in Rare Kidney Disorder FSGS; Shares Rally

Peer Comparison

Price change

Travere Therapeutics Inc Forecast

Price Target

By TipRanks

40.26% upside

12 Months Forecast

Average 34.77 USD  40.26%

High 47 USD

Low 25 USD

Based on 16 Wall Street analysts offering 12 month price targets forTravere Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

14

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

20.08 / 20.81Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat